ALPHA-LIPOIC ACID ( DrugBank: Lipoic acid, alpha-Lipoic acid )

---

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
2	筋萎縮性側索硬化症	1
13	多発性硬化症／視神経脊髄炎	1

2. 筋萎縮性側索硬化症

---

臨床試験数 : 645 /  薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2005-005152-40-IT (EUCTR)	19/04/2006	07/04/2006	MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, TRIAL ON ALPHA-LIPOIC ACID FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS ALALS - ALALS	MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, TRIAL ON ALPHA-LIPOIC ACID FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS ALALS - ALALS	ALS MedDRA version: 6.1;Level: PT;Classification code 10002026	Product Name: ALPHA-LIPOIC ACID INN or Proposed INN: Tioctic acid	AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	84		Italy

13. 多発性硬化症／視神経脊髄炎

---

臨床試験数 : 3,340 /  薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00010842 (ClinicalTrials.gov)	September 1999	2/2/2001	Natural Antioxidants in the Treatment of Multiple Sclerosis	Natural Antioxidants in the Treatment of Multiple Sclerosis	Multiple Sclerosis	Drug: Ginkgo biloba;Drug: Alpha-lipoic acid;Drug: Vitamin E/Selenium;Drug: Essential fatty acids	National Center for Complementary and Integrative Health (NCCIH)	NULL	Completed	N/A	N/A	Both		Phase 1/Phase 2	United States